Evidence map›Paper›PMID 32511370›Full record

ArticlebioRxiv : the preprint server for biology2020

Bepridil is potent against SARS-CoV-2 In Vitro.

Erol C Vatansever, Kai Yang, Kaci C Kratch, Aleksandra Drelich, Chia-Chuan Cho, Drake M Mellott, Shiqing Xu, Chien-Te K Tseng, Wenshe Ray Liu

Open access · greenAbstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in bioRxiv : the preprint server for biology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 30 citations in OpenAlex.

  1. Article
  2. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Erol C VatanseverThe Texas A&M Drug Discovery Laboratory, Department of Chemistry, Texas A&M University, College Station, TX 77843, USA.
Kai YangThe Texas A&M Drug Discovery Laboratory, Department of Chemistry, Texas A&M University, College Station, TX 77843, USA.
Kaci C KratchThe Texas A&M Drug Discovery Laboratory, Department of Chemistry, Texas A&M University, College Station, TX 77843, USA.
Aleksandra DrelichDepartment of Microbiology and Immunology, University of Texas Medical Branch, Galveston, TX 77555, USA.
Chia-Chuan ChoThe Texas A&M Drug Discovery Laboratory, Department of Chemistry, Texas A&M University, College Station, TX 77843, USA.
Drake M MellottDepartment of Biochemistry and Biophysics, Texas A&M University, College Station, TX 77843, USA.
Shiqing XuThe Texas A&M Drug Discovery Laboratory, Department of Chemistry, Texas A&M University, College Station, TX 77843, USA.
Chien-Te K TsengDepartment of Microbiology and Immunology, University of Texas Medical Branch, Galveston, TX 77555, USA.
Wenshe Ray LiuThe Texas A&M Drug Discovery Laboratory, Department of Chemistry, Texas A&M University, College Station, TX 77843, USA.
Texas A&M University · USThe University of Texas Medical Branch at Galveston · US

Funding

Develop General Methods for the Synthesis of Proteins with Posttranslational Lysine ModificationsR01GM127575 · NIGMS · TEXAS A&M UNIVERSITY · PI LIU, WENSHE RAY · 2019 to 2022
$1.4M
Studying Reversible Histone Acylations in Nucleosome ContextsR01GM121584 · NIGMS · TEXAS A&M UNIVERSITY · PI LIU, WENSHE RAY · 2017 to 2020
$1.3M
NIGMS NIH HHS R01 GM121584NIGMS NIH HHS R01 GM127575
6 · The paper itself

Abstract

Guided by a computational docking analysis, about 30 FDA/EMA-approved small molecule medicines were characterized on their inhibition of the SARS-CoV-2 main protease (M

Indexed as

bepridilCOVID-19drug repurposingmain proteaseSARS-CoV-2

Identifiers

PMID32511370
PMCPMC7263498
OpenAlexW3104452157

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.